報價延遲最少15分鐘:2026/04/21 20:02 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.46 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.09/0.88
|
|
企業價值
4.97B
|
| 資產負債 |
|
每股賬面淨值
0.87
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
634.21M
|
|
每股收益
1.19
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases. |
